his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide
Pregnant women between 20 and 36 weeks of gestation
Age between 18 and 45 years
Attending the antenatal clinic at the study site
Chronic hypertension
Renal disease
Diabetes mellitus
Multiple gestations
he study population will include pregnant women aged 18-45 years, between 20 and 36 weeks of gestation, attending the antenatal clinic at the study site. Participants will be divided into three groups: Pregnant women diagnosed with preeclampsia who have not yet received antihypertensive treatment. Pregnant women diagnosed with preeclampsia who are receiving antihypertensive treatment. Healthy pregnant women serving as control subjects. Exclusion criteria include pre-existing chronic hypertension, renal disease, diabetes mellitus, multiple gestations, or autoimmune disorders. All participants will provide informed consent before enrollment. Blood samples will be collected for biomarker analysis (sFlt-1, PlGF, soluble endoglin, and osteoprotegerin). This population has been selected to allow comparison of biomarker levels in different clinical scenarios and to evaluate their
Cohort
Prospective
Not listed
Serum sFlt-1 concentration
Measurement of serum sFlt-1 levels in maternal serum using ELISA
Serum PlGF concentration
Measurement of serum placental growth factor (PlGF) levels in maternal serum using ELISA.
sFlt-1/PlGF ratio
Calculated ratio of serum sFlt-1 to serum PlGF concentrations
Serum Osteoprotegerin (OPG) concentration
Measurement of serum osteoprotegerin (OPG) levels in maternal serum using ELISA.
Click on the lead sponsor to view all of their trials.
Ammar Jassim Abed
Lead sponsor
University of Thi-Qar
Sponsor institution
